Antonio Duran, MD
Advanced Heart Failure and Transplant Cardiology · Chula Vista, CANPI 1588027700
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (32.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Abbott at 51.9% of the total.
Across 358 payments — averaging $96.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$18K
- Bridgebio Pharma, Inc.$9K
- Johnson & Johnson$885
- Abiomed$879
- AstraZeneca$688
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$655
- plus $4K from 34 others
What the payments were for
- Speaking & faculty fees$9,08326%
- Grants$11,25033%
- Travel & lodging$3,46210%
- Food & beverage$10,53931%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 73 | $17,895 |
| Bridgebio Pharma, Inc. | 7 | $9,146 |
| Johnson & Johnson | 45 | $885 |
| Abiomed | 16 | $879 |
| AstraZeneca | 38 | $688 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $655 |
| E.r. Squibb & Sons, L.L.C. | 30 | $648 |
| Alnylam Pharmaceuticals Inc. | 17 | $383 |
| Boston Scientific | 4 | $345 |
| Pfizer | 15 | $290 |
| Edwards Lifesciences | 2 | $274 |
| Daiichi Sankyo Inc. | 13 | $262 |
| Novartis | 13 | $260 |
| Kestra Medical Technology Services, Inc. | 1 | $246 |
| Astellas Pharma US Inc | 7 | $194 |
| Amgen | 6 | $138 |
| Merck | 6 | $118 |
| Esperion Therapeutics, Inc. | 7 | $112 |
| Novo Nordisk | 4 | $102 |
| Medtronic | 3 | $97 |
| Scpharmaceuticals Inc. | 3 | $90 |
| Cvrx, Inc. | 4 | $73 |
| Cleerly, Inc. | 2 | $72 |
| Irhythm Technologies, Inc. | 3 | $67 |
| Boehringer Ingelheim | 3 | $67 |
| Sanofi-aventis U.S. LLC | 3 | $66 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $65 |
| Actelion Pharmaceuticals US, Inc. | 3 | $55 |
| Lexicon Pharmaceuticals, Inc. | 2 | $43 |
| Inspire Medical Systems, Inc. | 1 | $39 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Lilly USA, LLC | 1 | $25 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $24 |
| Endotronix, Inc. | 1 | $20 |
| Analog Devices Inc. | 1 | $20 |
| Biotronik Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
| Bayer | 1 | $14 |
| Livanova USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Attruby$9,083
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,710
- HeartMate Touch$1,091
- Impella$293
- LUX-Dx Insertable Cardiac Monitor$260
- SAPIEN 3 Ultra RESILIA$252
- Assure WCD$246
- XARELTO$152
- CAMZYOS$133
- AMVUTTRA$124
- CARDIOMEMS$121
- HeartMate 3 Left Ventricular Assist Device$118
- HeartMate 3 Left Ventricular Dev$109
- MitraClip$108
- LifeVest$104
How this compares
$34,449 in reported general payments places this provider in the 70th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $65,492 |
| EntrestoSacubitril/Valsartan | 32 | $54,005 |
| FarxigaDapagliflozin Propanediol | 29 | $36,216 |
| JardianceEmpagliflozin | 19 | $28,723 |
| BrilintaTicagrelor | 13 | $16,247 |
| Valsartan | 63 | $1,478 |
| Metoprolol Succinate | 87 | $1,171 |
| Rosuvastatin Calcium | 55 | $963 |
| Spironolactone | 78 | $847 |
| Nifedipine ErNifedipine | 36 | $820 |
| Atorvastatin Calcium | 56 | $722 |
| Losartan Potassium | 67 | $671 |
| Amlodipine Besylate | 58 | $527 |
| Carvedilol | 59 | $406 |
| Bumetanide | 20 | $327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $290 | $65,49246 claims |
| NovartisEntresto | $260 | $54,00532 claims |
| AstraZenecaFarxiga, Brilinta | $688 | $52,46342 claims |
| Boehringer IngelheimJardiance | $67 | $28,72319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in Chula Vista
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
- Marcus UreySan Diego$341K
- Munir JanmohamedSacramento$314K
- Barry GreenbergSan Diego$270K
- Ronald WittelesStanford$251K
- Gurpreet SodhiSacramento$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.